Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.

HYPOTHESIS Certain clinicopathologic factors predict improved survival after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. DESIGN Prospective clinical trial. SETTING Surgical oncology service at a university academic hospital. PATIENTS A population of 109 consecutive patients with peritoneal carcinomatosis treated between December 1991 and November 1997. INTERVENTION All patients underwent resection of gross disease followed by 2-hour intraoperative perfusion of mitomycin C (20-40 mg) into the peritoneal cavity at a temperature of 40.5 degrees C. MAIN OUTCOME MEASURES Clinicopathologic factors that independently predicted improved overall survival rates. RESULTS Overall survival at 1 and 3 years was 61% and 33%, respectively. With median follow-up of 52 months, median overall survival was 16 months. Four factors were significant independent predictors of improved survival by multivariate analysis: nonadenocarcinoma histologic features (P =.001), the appendix as a primary site (P =.003), the absence of hepatic parenchymal metastases (P =.01), and complete resection of all gross disease (R1/0 resection) (P<.001). Patients with an R1/0 resection vs an incomplete resection of gross disease (R2 resection) had 3-year overall survival of 68% vs 21% (P<.001). CONCLUSIONS Patients with peritoneal carcinomatosis have a uniformly poor prognosis. However, in select patients, the natural history of this disease condition may be altered by using the multimodality approach of cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. These results require confirmation in prospective randomized studies.

[1]  K. Geisinger,et al.  Prospective Trial for the Treatment of Malignant Peritoneal Mesothelioma , 2001, The American surgeon.

[2]  M. Ducreux,et al.  Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy , 2001, Cancer.

[3]  F. van Coevorden,et al.  Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. , 2001, European journal of cancer.

[4]  M. Manns,et al.  Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[5]  F. van Coevorden,et al.  Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei , 2001, The British journal of surgery.

[6]  S. Mocellin,et al.  Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  B. Loggie,et al.  Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[8]  P. Sugarbaker,et al.  Treatment of primary colon cancer with peritoneal carcinomatosis , 2000, Diseases of the colon and rectum.

[9]  D. Giannarelli,et al.  Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  F. Gilly,et al.  Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis , 2000, Cancer.

[11]  K. Geisinger,et al.  Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy for Disseminated Peritoneal Cancer of Gastrointestinal Origin , 2000, The American surgeon.

[12]  J. Faure,et al.  Peritoneal carcinomatosis from non‐gynecologic malignancies , 2000, Cancer.

[13]  P. Sugarbaker,et al.  Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy , 1999, Annals of Surgical Oncology.

[14]  J. Esquivel,et al.  Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique , 1999, Annals of Surgical Oncology.

[15]  S. Libutti,et al.  Treatment of Primary Peritoneal Mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP) , 1999, Annals of Surgical Oncology.

[16]  P. Schwartz,et al.  Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.

[17]  S. Libutti,et al.  A Phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis , 1998, Cancer.

[18]  K. Jablonski,et al.  Prognostic Features of 51 Colorectal and 130 Appendiceal Cancer Patients with Peritoneal Carcinomatosis Treated by Cytoreductive Surgery and Intraperitoneal Chemotherapy , 1995, Annals of surgery.

[19]  P. Sugarbaker.  Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. , 1994, Annals of surgery.

[20]  P. Sugarbaker,et al.  Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. , 1993, Surgery.

[21]  B. Shmookler,et al.  Peritoneal carcinomatosis from appendiceal cancer: Results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy , 1993, Diseases of the colon and rectum.

[22]  T. Kosaka,et al.  Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination , 1991, World Journal of Surgery.

[23]  K. Westbrook,et al.  Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors , 1989, Cancer.

[24]  Dedrick Rl.  Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985 .

[25]  C. Wong,et al.  Total abdominal irradiation for cancer of the colon. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  P. Ganz,et al.  Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R K Jain,et al.  Differential response of normal and tumor microcirculation to hyperthermia. , 1984, Cancer research.

[28]  G. Steel,et al.  Response of two mouse tumours to hyperthermia with CCNU or melphalan. , 1982, British Journal of Cancer.

[29]  B. Teicher,et al.  Enhancement by hyperthermia of the in vitro cytotoxicity of mitomycin C toward hypoxic tumor cells. , 1981, Cancer research.

[30]  J. Spratt,et al.  Clinical delivery system for intraperitoneal hyperthermic chemotherapy. , 1980, Cancer research.

[31]  N Gunduz,et al.  Effect of surgical removal on the growth and kinetics of residual tumor. , 1979, Cancer research.

[32]  L Simpson-Herren,et al.  Effects of surgery on the cell kinetics of residual tumor. , 1976, Cancer treatment reports.

[33]  B. Giovanella,et al.  Selective lethal effect of supranormal temperatures on human neoplastic cells. , 1976, Cancer research.

[34]  J. Mcvie,et al.  Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy , 2004, Cancer Chemotherapy and Pharmacology.

[35]  M. McCarter,et al.  Role for Surgical Cytoreduction in Multimodality Treatments for Cancer , 2001, Annals of Surgical Oncology.

[36]  R. Tanaka,et al.  Effects of antineoplastic agents and hyperthermia on cytotoxicity toward chronically hypoxic glioma cells. , 1992, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[37]  M. Markman.  Intraperitoneal therapy in ovarian cancer utilizing agents achieving high local but low systemic exposures , 1991 .

[38]  R. Dedrick,et al.  Theoretical and experimental bases of intraperitoneal chemotherapy. , 1985, Seminars in oncology.